UBS Group Reiterates “€59.00” Price Target for Fresenius SE & Co KGaA (FRA:FRE)

Share on StockTwits

UBS Group set a €59.00 ($68.60) target price on Fresenius SE & Co KGaA (FRA:FRE) in a report published on Thursday, July 19th, www.boersen-zeitung.de reports. The firm currently has a sell rating on the stock.

Several other equities research analysts also recently weighed in on FRE. Berenberg Bank set a €81.85 ($95.17) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Monday, June 18th. Deutsche Bank set a €82.00 ($95.35) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Thursday, July 19th. Sanford C. Bernstein set a €83.00 ($96.51) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, July 9th. Goldman Sachs Group set a €72.00 ($83.72) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, June 18th. Finally, Nord/LB set a €82.00 ($95.35) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, July 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of €78.78 ($91.61).

Shares of Fresenius SE & Co KGaA traded down €1.54 ($1.79), reaching €64.70 ($75.23), on Thursday, MarketBeat reports. The company had a trading volume of 2,020,041 shares. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply